# Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

> **NCT05118776** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ascletis Pharmaceuticals Co., Ltd.** · enrollment: 136 (actual)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** ASC40 tablets
- **DRUG:** Placebo tablets
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05118776
- **Lead sponsor:** Ascletis Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-21
- **Primary completion:** 2025-06
- **Final completion:** 2025-06
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05118776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05118776, "Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05118776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*